Search results
Earnings call: Harmony Biosciences maintains strong growth, eyes future launches
Investing.com· 6 days agoHarmony Biosciences (ticker: HRMY) has reported a solid start to the year with a 30% increase in...
Sweet Harmony: Neuro biotech buys Epygenix and its epilepsy meds for $35M upfront
FierceBiotech· 6 days agoHarmony Biosciences is adding a suite of epilepsy assets to its pipeline, buying Epygenix for $35 million upfront with more than $600 million in biobucks on the table. The relatively small M ...
Earnings call: Alkermes reports solid Q1 2024 results, optimistic about pipeline By Investing.com
Investing.com· 5 days agoThe neuroscience company reported net sales for VIVITROL at $97.7 million, ARISTADA at $78.9...
A little-understood sleep disorder affects millions and has clear links to dementia – 4 questions...
The Conversation via Yahoo News· 1 day agoWe also recommend measures to avoid injury, such as removing breakable objects from the room,...
Harmony Biosciences posts 30% revenue growth in Q1
Investing.com· 6 days agoThe company's adjusted earnings per share (EPS) of $0.88 also surpassed analyst expectations by $0.25... company's financial performance was bolstered by...
Alkermes plc Reports First Quarter 2024 Financial Results
NBC 10 - FOX 14 Monroe· 5 days agoAlkermes plc (Nasdaq: ALKS) today reported financial results for the first quarter of 2024. With these new data now in hand, we plan to initiate a phase 2 study in narcolepsy type 2 in the second half of 2024.
Needham raises Harmony Biosciences stock target on growth strategy By Investing.com
Investing.com· 5 days ago(NASDAQ: NASDAQ:HRMY) to $52, up from the previous $50, while maintaining a Buy rating on the stock....
Alkermes' (ALKS) Q1 Earnings & Revenues Fall Shy of Estimates
Zacks via Yahoo Finance· 4 days agoRecent Updates Last month, Alkermes announced positive top-line data from a phase Ib study...
Harmony Biosciences (HRMY) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 6 days agoWe are also pursuing new indications for pitolisant including near-term catalysts in pediatric ...
Harmony Biosciences Exceeds Analyst Revenue Forecasts While Aligning with EPS Projections in Q1 2024
GuruFocus.com via Yahoo Finance· 6 days agoTheir flagship product, WAKIX (pitolisant), has been a critical driver of revenue growth,...